CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...
Neurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $75 to $150, according to analysts polled by Capital IQ....
Neurocrine Biosciences (NBIX) entered into privately negotiated transactions to repurchase about $179.4 million of its existing 2.25% convertible senior...
Neurocrine Biosciences (NBIX) said late Thursday the US Food and Drug Administration granted an orphan drug designation to valbenazine for the potential...
Richard F Pops, Director, on May 09, 2022, sold 15,000 shares in Neurocrine Biosciences (NBIX) for $1,144,463. Following the Form 4 filing with the SEC,...
Expected Earnings Release: 05/04/2022, After-hours Avg. Extended-Hours Dollar Volume: $11,976,203 Neurocrine Biosciences (NBIX) is due to issue its...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Neurocrine Biosciences (NBIX) reported Wednesday Q1 non-GAAP earnings of $0.30 per share, compared with $0.50 a year earlier. Analysts polled by Capital IQ...
...
...